Pharmaceutical - Anti-virals


Current filters:


Popular Filters

126 to 150 of 307 results

Boehringer Ingelheim's all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C


New data from German family-owned drug major Boehringer Ingelheim's interferon-free SOUND-C3, presented…

Anti-viralsBoehringer IngelheimdeleobuvirfaldaprevirPharmaceuticalResearch

Bionor Pharma leaps on positive trial results of HIV vaccine Vacc-4x with Revlimid


Norway-based Bionor Pharma (OSE: BIONOR) saw its shares leap 16% to 3.67 kroner on June 13, after the…

Anti-viralsBionor PharmaCelgenePharmaceuticalResearchRevlimidVacc-4xVaccines

BioLineRx collaborates with Chinese firm on hep C drug BL-8030


Israeli drug developer BioLineRx (TASE: BLRX) has signed an out-licensing agreement with Jiangsu Chia-tai…

Anti-viralsAsia-PacificBioLineRxBiotechnologyBL-8030Chia-tai Tianqing PharmaceuticalLicensingPharmaceutical

BioAlliance Pharma' Sitavig shows marked efficacy in treating cold sores


French drugmaker BioAlliance Pharma (Euronext Paris: BIO) has presented positive results of the pharmacokinetic…

Anti-viralsBioAlliance PharmaPharmaceuticalResearchSitavig

HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst


While the risks involved in HIV vaccine development have turned Big Pharma away from pursuing a preventative…

Anti-viralsBiotechnologyFinancialHVTN 505PharmaceuticalResearchVaccines

Encouraging results with Sangamo's SB-728-T in HIV treatment


USA-based Sangamo BioSciences (Nasdaq: SGMO) has presented new clinical data from its program to develop…


US FDA grants "Breakthrough" status for AbbVie's HCV regimen


US drugmaker AbbVie (NYSE: ABBV) says that its investigational direct-acting antiviral (DAA) combination…


US and European gastroenterologist's views on hepatitis C treatments


Gastroenterologists in the USA and Europe by health care advisory firm Decision Resources agree that…

Anti-viralsBiotechnologyEuropeMarkets & MarketingNorth AmericaPharmaceuticalResearch

Combination drugs will drive Europe's hepatitis B and C therapeutics markets, says F&S


The limited efficacy and negative side effects associated with current therapeutics for hepatitis B and…

Anti-viralsEuropeMarkets & MarketingPharmaceuticalResearch

US NIH unit halts most advanced HIV vaccine study on poor results


The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes…

Anti-viralsNorth AmericaPharmaceuticalResearch

Janssen files for European approval of hep C candidate simeprevir


Janssen-Cilag International, a European subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ),…

Anti-viralsBiotechnologyEuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationsimeprevir

New drug candidates hold promise for European HIV drugs market, says F&S


The anticipated launch of drugs currently in the pipeline, together with the introduction of oral combination…

Anti-viralsEuropeMarkets & MarketingPharmaceutical

BioAlliance Pharma's Sitavig OKed by US FDA for Herpes labialis


French drugmaker BioAlliance Pharma (Euronext Paris - BIO) has received marketing authorization from…

Anti-viralsBioAlliance PharmaNorth AmericaPharmaceuticalRegulationSitavig

Roche teams up with Ascletis on hep C treatments for China


Roche (ROG: SIX) has entered a collaboration with Ascletis Pharmaceuticals, a USA- and China-based biotech…

Anti-viralsAscletis PharmaceuticalsAsia-PacificBiotechnologydanoprevirLicensingMarkets & MarketingPharmaceuticalResearchRoche

126 to 150 of 307 results

Back to top